JP7805651B2 - 抗腫瘍アスコルビン酸エステル - Google Patents

抗腫瘍アスコルビン酸エステル

Info

Publication number
JP7805651B2
JP7805651B2 JP2023515364A JP2023515364A JP7805651B2 JP 7805651 B2 JP7805651 B2 JP 7805651B2 JP 2023515364 A JP2023515364 A JP 2023515364A JP 2023515364 A JP2023515364 A JP 2023515364A JP 7805651 B2 JP7805651 B2 JP 7805651B2
Authority
JP
Japan
Prior art keywords
compound
esi
cancer
mmol
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023515364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541840A (ja
JP2023541840A5 (https=
Inventor
バルゲス，テレサ ロヨ
ディオップ，ヤガマレ フォール
パシオス，マリア ゲネロサ デ ロス アンヘレス ゴメス
ガルシア，ヒューゴ サンターリャ
フェルナンデス，ファティマ ガリド
クルツ，グイド
ロヨ，マリア ルビエス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suigeneris Farmacosmetics SL
Original Assignee
Suigeneris Farmacosmetics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suigeneris Farmacosmetics SL filed Critical Suigeneris Farmacosmetics SL
Publication of JP2023541840A publication Critical patent/JP2023541840A/ja
Publication of JP2023541840A5 publication Critical patent/JP2023541840A5/ja
Application granted granted Critical
Publication of JP7805651B2 publication Critical patent/JP7805651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023515364A 2020-09-14 2021-09-13 抗腫瘍アスコルビン酸エステル Active JP7805651B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382804.1A EP3967684A1 (en) 2020-09-14 2020-09-14 Antitumoral ascorbic acid esters
EP20382804.1 2020-09-14
PCT/EP2021/075104 WO2022053679A1 (en) 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters

Publications (3)

Publication Number Publication Date
JP2023541840A JP2023541840A (ja) 2023-10-04
JP2023541840A5 JP2023541840A5 (https=) 2024-09-24
JP7805651B2 true JP7805651B2 (ja) 2026-01-26

Family

ID=72709280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515364A Active JP7805651B2 (ja) 2020-09-14 2021-09-13 抗腫瘍アスコルビン酸エステル

Country Status (10)

Country Link
US (1) US20230278974A1 (https=)
EP (2) EP3967684A1 (https=)
JP (1) JP7805651B2 (https=)
KR (1) KR20230088718A (https=)
CN (1) CN116724028B (https=)
AU (1) AU2021339010A1 (https=)
CA (1) CA3191119A1 (https=)
ES (1) ES3006988T3 (https=)
MX (1) MX2023002970A (https=)
WO (1) WO2022053679A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4676461A1 (en) * 2023-03-09 2026-01-14 Mastery Biotech Co., Ltd. Conjugate compound comprising 13-cis-retinoic acid and ascorbic acid

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526151A (ja) 2009-05-11 2012-10-25 ▲無▼▲錫▼宏瑞生物医▲薬▼科技有限公司 アリルプロピオン酸系ビタミンｃステアレート、その調製方法及びそれらを含有する薬物
JP2016104708A (ja) 2014-12-01 2016-06-09 参天製薬株式会社 アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
JP2016138087A (ja) 2015-01-26 2016-08-04 公立大学法人県立広島大学 抗腫瘍剤
CN106139151A (zh) 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物
WO2018026673A1 (en) 2016-08-01 2018-02-08 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2831395B2 (ja) * 1989-09-12 1998-12-02 ハリマ化成株式会社 アスコルビン酸エステル
JP3781877B2 (ja) * 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526151A (ja) 2009-05-11 2012-10-25 ▲無▼▲錫▼宏瑞生物医▲薬▼科技有限公司 アリルプロピオン酸系ビタミンｃステアレート、その調製方法及びそれらを含有する薬物
JP2016104708A (ja) 2014-12-01 2016-06-09 参天製薬株式会社 アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
JP2016138087A (ja) 2015-01-26 2016-08-04 公立大学法人県立広島大学 抗腫瘍剤
CN106139151A (zh) 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物
WO2018026673A1 (en) 2016-08-01 2018-02-08 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer

Also Published As

Publication number Publication date
CA3191119A1 (en) 2022-03-17
KR20230088718A (ko) 2023-06-20
ES3006988T3 (en) 2025-03-19
EP4211123C0 (en) 2024-11-06
JP2023541840A (ja) 2023-10-04
CN116724028B (zh) 2025-07-08
WO2022053679A1 (en) 2022-03-17
US20230278974A1 (en) 2023-09-07
AU2021339010A1 (en) 2023-03-23
EP4211123A1 (en) 2023-07-19
CN116724028A (zh) 2023-09-08
EP4211123B1 (en) 2024-11-06
EP3967684A1 (en) 2022-03-16
MX2023002970A (es) 2023-05-15

Similar Documents

Publication Publication Date Title
EP3029043B1 (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof
KR102579485B1 (ko) 5-아자사이티딘류의 당 부분(糖部) 실릴에테르 유도체
CN112804995A (zh) 隐杯伞素类似物、其应用及其合成方法
JP2015502974A (ja) 抗微生物療法のための三環式ホウ素化合物
EP2924042A1 (en) Bis- -carboline compound and preparation method, pharmaceutical composition and use thereof
WO2018133661A1 (zh) 一种新的硼酸衍生物及其药物组合物
US9738613B2 (en) Substituted 1,2,3-triazoles as antitumor agents
CN102010421A (zh) 青蒿素类衍生物及其应用
US20210085640A1 (en) Acylated catechin polyphenols and methods of their use for the treatment of cancer
JP7805651B2 (ja) 抗腫瘍アスコルビン酸エステル
EP2617714B1 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
CN103965175B (zh) 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用
EP3978473B1 (en) Compound containing an indoleacetic acid core structure and use thereof
EP1902054B1 (fr) Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique
JP5701387B2 (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用
CN114380864A (zh) 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用
EP1911451A1 (en) Protein-kinase CK2 inhibitors and their therapeutic applications
CN115403497A (zh) 新型含有金刚烷骨架席夫碱衍生物的合成及抗肿瘤活性研究
CN113861214A (zh) 1,2,3-三唑栓系双氢青蒿素-靛红杂化物及其制备方法和应用
CN1337966A (zh) 具有提高的生物利用度的橙皮素前体
EP2313363A2 (en) Lipid compounds for supression of tumorigenesis
US20160102066A1 (en) Benzothiazole derivative and anti-tumor use thereof
WO2010090234A1 (ja) 12-デオキシフシコクシン糖鎖改変誘導体およびその用途
JP5034039B2 (ja) Ｇｍ３類似体
EP3194360B1 (en) 4-oxo-n-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260106

R150 Certificate of patent or registration of utility model

Ref document number: 7805651

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150